<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03401502</url>
  </required_header>
  <id_info>
    <org_study_id>TSHRN1701</org_study_id>
    <nct_id>NCT03401502</nct_id>
  </id_info>
  <brief_title>A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency</brief_title>
  <official_title>A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency in Patients With Stable Angina Pectoris.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TSH Biopharm Corporation Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TSH Biopharm Corporation Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, and parallel study. The study is&#xD;
      comprised of three main phases: a single-blind placebo run-in qualifying phase lasting about&#xD;
      14 days, a double-blind treatment phase of 12 weeks, and a 2-week follow-up phase.&#xD;
      Approximately 18 patients will be enrolled and randomly assigned to receive placebo or 1,000&#xD;
      mg of extended-release Ranolazine twice-daily for 12 weeks to reach 14 evaluable patients at&#xD;
      the end of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, and parallel study. The study is&#xD;
      comprised of three main phases: a single-blind placebo run-in qualifying phase lasting about&#xD;
      14 days, a double-blind treatment phase of 12 weeks, and a 2-week follow-up phase.&#xD;
      Approximately 18 patients will be enrolled and randomly assigned to receive placebo or 1,000&#xD;
      mg of extended-release Ranolazine twice-daily for 12 weeks to reach 14 evaluable patients at&#xD;
      the end of the study.&#xD;
&#xD;
      Patients with chronic angina pectoris will be screened for eligibility after providing&#xD;
      informed consent. Patients present with the symptoms of stable angina after withdrawn from&#xD;
      other antianginal agents and given the required background therapy for at least 5 days will&#xD;
      be qualified for entering this study and performing 1st ETT qualifying test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2018</start_date>
  <completion_date type="Actual">March 31, 2019</completion_date>
  <primary_completion_date type="Actual">March 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Treatment group:Ranolazine 1000 mg:&#xD;
Control group: Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>ETT performing duration</measure>
    <time_frame>at trough (12 hours after dosing) at Week 12</time_frame>
    <description>To compare the change from baseline of ETT performing duration between add-on Ranolazine and placebo</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Angina</condition>
  <arm_group>
    <arm_group_label>Treatment groups</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranolazine 1000 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebos</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Oral, b.i.d</description>
    <arm_group_label>Treatment groups</arm_group_label>
    <other_name>RNTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Oral, b.i.d</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients aged ≥ 20 years old.&#xD;
&#xD;
          2. A minimum 3-month history of stable angina.&#xD;
&#xD;
          3. Patients with diagnosis of coronary artery disease (CAD) via at least one of the&#xD;
             following criteria:&#xD;
&#xD;
               -  Angiographic evidence of ≥ 50% stenosis of ≥ 1 major coronary artery;&#xD;
&#xD;
               -  CT angiographic evidence of ≥ 50% stenosis of ≥ 1 major coronary artery;&#xD;
&#xD;
               -  History of previous myocardial infarction (MI)*;&#xD;
&#xD;
                  *Previous MI history of patients has to be occurred and diagnosed at least 2&#xD;
                  months prior entering this study.&#xD;
&#xD;
               -  A stress-induced reversible perfusion defect identified by radionuclide or&#xD;
                  echocardiographic imaging.&#xD;
&#xD;
          4. Patients present with the symptoms of stable angina after withdrawn from other&#xD;
             antianginal drugs and given the required background therapy for at least 5 days will&#xD;
             be qualified for entering this study and performing 1st ETT qualifying test.&#xD;
&#xD;
          5. Patients developed exercise-induced ECG ischemia during two qualifying exercise&#xD;
             treadmill tests. The difference between twotests should be ≤ 20% of the longer test or&#xD;
             ≤ 1 minute.&#xD;
&#xD;
          6. Willing and able to provide a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Factors that might compromise ECG or ETT interpretation.&#xD;
&#xD;
               -  Patients with resting ST-segment depression ≥ 1mm in any lead.&#xD;
&#xD;
               -  Left bundle-branch block.&#xD;
&#xD;
               -  Patients implanted with pacemaker.&#xD;
&#xD;
               -  Patients under Digitalis therapy.&#xD;
&#xD;
          2. Patients with family history of (or congenital) long QT syndrome.&#xD;
&#xD;
          3. Patients with congenital heart disease.&#xD;
&#xD;
          4. Patients with uncorrected valvular heart disease.&#xD;
&#xD;
          5. Patients with unstable angina, or MI, or coronary revascularization procedure ≤ 2&#xD;
             months prior enter this study.&#xD;
&#xD;
          6. Female who is pregnant/lactating or planning to be pregnant, or female of childbearing&#xD;
             potential* who is not using medically recognized method of contraception.&#xD;
&#xD;
             *Other than those who have been surgically sterilized (defined as having undergone&#xD;
             hysterectomy or bilateral oophorectomy or bilateral salpingectomy; tubal ligation&#xD;
             alone is not considered sufficient) or one year post-menopausal.&#xD;
&#xD;
          7. Patients are under any one of the following conditions:&#xD;
&#xD;
               -  New York Heart Association (NYHA) Class III or Class IV congestive heart failure&#xD;
                  (CHF);&#xD;
&#xD;
               -  QTc &gt; 450 msec at screening;&#xD;
&#xD;
               -  Active myocarditis, pericarditis, hypertrophic cardiomyopathy;&#xD;
&#xD;
               -  Uncontrolled hypertension (defined as SBP &gt; 180 mmHg). Voltage criteria for left&#xD;
                  ventricular hypertrophy in the absence of repolarization abnormalities will not&#xD;
                  be exclusion criteria.&#xD;
&#xD;
          8. Use of any investigational product ≤ 4 weeks prior to screening.&#xD;
&#xD;
          9. Patients with severe hepatic disease (e.g., liver cirrhosis).&#xD;
&#xD;
         10. Patients with impaired renal function (defined as serum Cr &gt;1.5 mg/dl).&#xD;
&#xD;
         11. Patients with any condition or disease which is considered not suitable for this study&#xD;
             by investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Zhongzheng Dist</state>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 7, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

